To explore the therapeutic efficacy of human VEGFR-2 LDC, we treated mice either 13 days (CT26 tumors) or 4 days (4T1 tumors) after the implantation of tumor cells, when the tumors were palpable. The gene discussed is KDR; the disease is neoplasm.